Skip to content

Mounjaro

Also called tirzepatide injection, Mounjaro pen, Zepbound.

By Dr Chad Okay4 min read

Mounjaro is the brand name Eli Lilly uses for tirzepatide injections, taken once a week. It is a dual agonist that activates both GLP-1 and GIP receptors. In the UK it is licensed for type 2 diabetes and, separately, for weight management. In trials it produces slightly more weight loss than semaglutide (Wegovy), with similar gut side effects.

What Mounjaro is

Mounjaro is tirzepatide, a single molecule that binds to two different gut hormone receptors at once: GLP-1 (the same target as semaglutide) and GIP. Both hormones are released by the small intestine after meals. Activating both is thought to amplify the effects on insulin release, gastric emptying, and appetite. In the US the same drug is sold for weight loss under the brand Zepbound.

How it compares to Wegovy

  • Average weight loss in the SURMOUNT-1 trial: 22.5% at 72 weeks on the 15 mg dose (NEJM headline; NICE cites 20.9% under a stricter treatment-regimen estimand). The 2025 SURMOUNT-5 head-to-head trial showed tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks.
  • Side effect profile is similar: nausea, constipation, reflux, fatigue.
  • Dose schedule is similar: a slow titration over 4 to 5 months.
  • Both are weekly injections. The pens look almost identical.
  • In the UK, NICE recommends tirzepatide for weight management in eligible adults; it can be used in primary care or specialist weight management services.

The dose ladder

  1. Week 1 to 4: 2.5 mg weekly. Starter dose, tolerance only.
  2. Week 5 to 8: 5 mg weekly. First meaningful dose.
  3. Week 9 to 12: 7.5 mg weekly.
  4. Week 13 to 16: 10 mg weekly.
  5. Week 17 to 20: 12.5 mg weekly.
  6. Week 21 onwards: 15 mg weekly maintenance dose.

Side effects

  • Nausea, peaking after each dose increase and usually settling in 1 to 2 weeks.
  • Constipation. Slowed gut transit is part of the mechanism. It was a frequent gastrointestinal side effect across the tirzepatide doses in the SURMOUNT trials. Hydration and fibre matter.
  • Diarrhoea in a minority, usually early on.
  • Reflux from food sitting longer in the stomach.
  • Injection-site reactions: small bumps or itching, almost always self-resolving.
  • Rare but serious: pancreatitis, gallstones, severe gastroparesis. Severe, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).

If something feels wrong

This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

What is still unknown

The dedicated cardiovascular outcomes trial in type 2 diabetes (SURPASS-CVOT, published December 2025) found tirzepatide non-inferior to dulaglutide for major cardiovascular events. Long-term safety in people without diabetes who take it for weight management is less well characterised than for semaglutide. Both drugs are extremely new in the population history of medication, which is worth keeping in mind when reading anecdote-driven press coverage.

Common questions

Different molecules. Tirzepatide (Mounjaro) tends to produce slightly more weight loss in head-to-head trials. Semaglutide (Ozempic, Wegovy) has more years of post-launch data. The right choice depends on what the drug is being prescribed for, supply availability in the UK, and how each person tolerates side effects.

Built for this.

Suna is a wearable designed to help you see your own everyday patterns, without keeping a diary. Reservations open.

Sources

  1. 1Mounjaro KwikPen 15mg solution for injection - Summary of Product CharacteristicsEMC (UK)
  2. 2NICE TA1026 recommendations: tirzepatide for managing overweight and obesityNICE
  3. 3SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff et al, 2022)New England Journal of Medicine / PubMed
  4. 4SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (Aronne et al, 2025), 20.2% vs 13.7% at week 72New England Journal of Medicine (PubMed)
  5. 5Tirzepatide - StatPearls (dual GIP/GLP-1 receptor agonist mechanism)StatPearls / NCBI Bookshelf
  6. 6Gastrointestinal tolerability of tirzepatide in the SURMOUNT-1 to -4 trials (Rubino et al, 2025)Diabetes, Obesity and Metabolism / PMC
  7. 7SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, Nicholls et al, 2025 (non-inferior)New England Journal of Medicine (PubMed)
  8. 8Mounjaro (tirzepatide) prescribing information: oral hormonal contraceptives and delayed gastric emptyingEli Lilly
  9. 9Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Related reading

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.